drugset / Trial / NCT01551602

Clinical Study of AK159 in Healthy Postmenopausal Women

NCT01551602

Phase 1 Completed 132 enrolled Asahi Kasei Therapeutics Corporation
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The objective of this study is to investigate the pharmacokinetics, safety, and tolerability of AK159 administered to healthy postmenopausal women.

Timeline

Start
2012-03
Primary completion
2012-09
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriparatide Protein / enzyme biologic Other

Indications